[Dermatological implications of the PI3K pathway]

Ann Dermatol Venereol. 2015 Oct;142(10):622-3. doi: 10.1016/j.annder.2015.04.019. Epub 2015 May 19.
[Article in French]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Division / physiology
  • Hamartoma / enzymology
  • Hamartoma Syndrome, Multiple / enzymology
  • Humans
  • Melanoma / drug therapy
  • Melanoma / enzymology
  • Melanoma / secondary
  • Molecular Targeted Therapy
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / physiology
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / physiology*
  • Protein Kinase Inhibitors / therapeutic use
  • Proteus Syndrome / enzymology
  • Proto-Oncogene Proteins c-akt / physiology
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Signal Transduction / physiology*
  • Skin Diseases / classification
  • Skin Diseases / drug therapy
  • Skin Diseases / enzymology*
  • Skin Diseases / genetics
  • Skin Diseases / pathology
  • Syndrome
  • TOR Serine-Threonine Kinases / physiology

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • MTOR protein, human
  • PIK3C2A protein, human
  • AKT1 protein, human
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • PTEN Phosphohydrolase
  • PTEN protein, human